M A Martinez-García1, G Oscullo2, T Posadas2, E Zaldivar2, C Villa3, Y Dobarganes3, R Girón4, C Olveira5, L Maíz6, M García-Clemente7, O Sibila8, R Golpe9, J Rodríguez10, E Barreiro11, J L Rodriguez12, L Feced-Olmos2, C Prados13, A Muriel14, D de la Rosa15. 1. Respiratory Department, Hospital Universitario y Politecnico La Fe, Valencia, Spain; CIBER de enfermedades respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. Electronic address: mianmartinezgarcia@gmail.com. 2. Respiratory Department, Hospital Universitario y Politecnico La Fe, Valencia, Spain. 3. Respiratory Department, Clinica Fuensanta, Madrid, Spain. 4. Respiratory Department, Hospital la Princesa, Madrid, Spain. 5. Respiratory Department, Hospital Regional de Málaga, Málaga, Spain. 6. Respiratory Department, Hospital Ramon y Cajal, Madrid, Spain. 7. Respiratory Department, Hospital de Oviedo, Oviedo, Spain. 8. Respiratory Department, Hospital Santa Creu I Sant Pau, Barcelona, Spain. 9. Respiratory Department, Hospital Lucus Augusti, Lugo, Spain. 10. Respiratory Department, Hospital San Agustin, Aviles, Spain. 11. Respiratory Department, Hospital del Mar, Barcelona, Spain. 12. Respiratory Department, Hospital San Carlos, Madrid, Spain. 13. Respiratory Department, Hospital la Paz, Madrid, Spain. 14. Biostatistic Unit, Hospital Ramón y Cajal, IRYCIS, CIBERESP, Nursery Department and Physiotherapy, Alcalá University, Madrid, Spain. 15. Respiratory Department, Hospital Plató, Barcelona, Spain.
Abstract
OBJECTIVES: The objective of this study was to analyse lung function decline over time in bronchiectasis, along with the factors associated with it. METHODS: Spirometry was measured every year in this observational, prospective study in 849 patients from the Spanish Bronchiectasis Registry (RIBRON). The main outcome was the decline in the rate of forced expiratory volume during the first second (FEV1). To be included in this study, patients needed a baseline assessment and at least one subsequent assessment. FEV1 decline was analysed using a mixed-effects linear regression model adjusted for clinically significant variables. RESULTS: We recruited 849 bronchiectasis patients with at least two annual lung function measurements (follow-up range 1-4 years). A total of 2262 lung function tests were performed (mean 2.66 per patient, range 2-5). Mean baseline FEV1 was 1.78 L (standard deviation (SD) 0.76; 71.3% predicted). Mean age was 69.1 (SD 15.4) years; 543 (64% women. The adjusted rates of FEV1 decline were -0.98% predicted/year (95% confidence interval (CI) -2.41 to -0.69) and -31.6 (95% CI -44.4 to -18.8) mL. The annual FEV1 decline was faster in those patients with chronic bronchial infection by Pseudomonas aeruginosa (-1.37% (52.1 mL) vs -0.37% (-24.6 mL); p < 0.001), greater age, increased number of severe exacerbations in the previous year and higher baseline FEV1 value. DISCUSSION: In patients with bronchiectasis, the annual rate of FEV1 decline was -31.6 mL/year and it was faster in older patients and those with chronic bronchial infection by P. aeruginosa, increased number of previous severe exacerbations and higher baseline FEV1 value.
OBJECTIVES: The objective of this study was to analyse lung function decline over time in bronchiectasis, along with the factors associated with it. METHODS: Spirometry was measured every year in this observational, prospective study in 849 patients from the Spanish Bronchiectasis Registry (RIBRON). The main outcome was the decline in the rate of forced expiratory volume during the first second (FEV1). To be included in this study, patients needed a baseline assessment and at least one subsequent assessment. FEV1 decline was analysed using a mixed-effects linear regression model adjusted for clinically significant variables. RESULTS: We recruited 849 bronchiectasis patients with at least two annual lung function measurements (follow-up range 1-4 years). A total of 2262 lung function tests were performed (mean 2.66 per patient, range 2-5). Mean baseline FEV1 was 1.78 L (standard deviation (SD) 0.76; 71.3% predicted). Mean age was 69.1 (SD 15.4) years; 543 (64% women. The adjusted rates of FEV1 decline were -0.98% predicted/year (95% confidence interval (CI) -2.41 to -0.69) and -31.6 (95% CI -44.4 to -18.8) mL. The annual FEV1 decline was faster in those patients with chronic bronchial infection by Pseudomonas aeruginosa (-1.37% (52.1 mL) vs -0.37% (-24.6 mL); p < 0.001), greater age, increased number of severe exacerbations in the previous year and higher baseline FEV1 value. DISCUSSION: In patients with bronchiectasis, the annual rate of FEV1 decline was -31.6 mL/year and it was faster in older patients and those with chronic bronchial infection by P. aeruginosa, increased number of previous severe exacerbations and higher baseline FEV1 value.
Authors: Marta Garcia-Clemente; David de la Rosa; Luis Máiz; Rosa Girón; Marina Blanco; Casilda Olveira; Rafael Canton; Miguel Angel Martinez-García Journal: J Clin Med Date: 2020-11-24 Impact factor: 4.241
Authors: Xuejie Wang; Carmen Villa; Yadira Dobarganes; Casilda Olveira; Rosa Girón; Marta García-Clemente; Luis Máiz; Oriol Sibila; Rafael Golpe; Rosario Menéndez; Juan Rodríguez-López; Concepción Prados; Miguel Angel Martinez-García; Juan Luis Rodriguez; David de la Rosa; Xavier Duran; Jordi Garcia-Ojalvo; Esther Barreiro Journal: Biomedicines Date: 2022-01-21
Authors: Marta García Clemente; Casilda Olveira; Rosa Girón; Luis Máiz; Oriol Sibila; Rafael Golpe; Rosario Menéndez; Juan Rodríguez; Esther Barreiro; Juan Luis Rodríguez Hermosa; Concepción Prados; David De la Rosa; Claudia Madrid Carbajal; Marta Solís; Miguel Ángel Martínez-García Journal: J Clin Med Date: 2022-07-07 Impact factor: 4.964